Skip to Content

Publications Search - Abstract View

Title: Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
Authors: Freedman ND,  Everhart JE,  Lindsay KL,  Ghany MG,  Curto TM,  Shiffman ML,  Lee WM,  Lok AS,  Di Bisceglie AM,  Bonkovsky HL,  Hoefs JC,  Dienstag JL,  Morishima C,  Abnet CC,  Sinha R,  HALT-C Trial Group,  Szabo G,  Banner BF,  Cormier M,  Giansiracusa D,  Kelley M,  Bacon B,  Neuschwander-Tetri B,  Brunt EM,  King D,  Chung RT,  Reid AE,  Bhan AK,  Molchen WA,  Everson GT,  Nash SR,  DeSanto J,  McKinley C,  Morgan TR,  Craig JR,  Jamal MM,  Sheikh M,  Park C,  Rogers TE,  Shelton J,  Crowder N,  Elbein R,  Liston N,  Govindarajan S,  Jones CB,  Milstein SL,  Fontana RJ,  Greenson JK,  Richtmyer PA,  Bonham RT,  Sterling RK,  Contos MJ,  Mills AS,  Hofmann C,  Smith P,  Liang TJ,  Kleiner D,  Park Y,  Rivera E,  Haynes-Williams V,  Seeff LB,  Robuck PR,  Hoofnagle JH,  Wright EC,  Gretch DR,  Chung Apodaca M,  Shankar R,  Snow KK,  Stoddard AM,  Bell MC,  Goodman ZD,  Garcia-Tsao G,  Kutner M,  Lemon SM,  Perrillo RP
Journal: Hepatology
Date: 2009 Nov
Branches: NEB
PubMed ID: 19676128
PMC ID: PMC2783828
Abstract: UNLABELLED: Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C-related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C-related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 or more cups/day (P-trend = 0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76-1.61) for less than 1 cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. CONCLUSION: In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression.